After the initial biochemical synthesis and chemical evaluations of your tracer, we start the preclinical evaluation process by testing your compound in vitro in human cancer cell lines or transgenic cell lines of the target of interest. Items like binding and blocking experiments are at your disposal including FACS analyses and/or state-of-the-art fluorescence microscopy. Subsequently, we enter the in vivo preclinical evaluation stage in which we implant (bioluminescent) human cancer cell lines in small animals for dose-finding, pharmacokinetic, pharmacodynamic and biodistribution data analyses.
We have access to the latest imaging systems for simultaneous bioluminescence and fluorescence imaging (i.e. IVIS Spectrum) and quantitative fluorescence imaging (i.e. FMT2500). Moreover, for image-guided surgery or flexible endoscopy applications, dedicated translational intraoperative, laproscopy and flexible endoscopy optical imaging systems are available (i.e. SurgVision, Olympus, Mauna Kea and Novadaq), which provide the necessary stepping-stones towards clinical evaluation. Further, all the excised specimen is examined ex vivo with the same systems used for clinical evaluation i.e. SurgVision Explorer Air, LI-COR Odyssey flatbed scanner and/or a Leica Near-Infrared fluorescence microscopy. After the initial preclinical evaluation has proven successful in vitro and in vivo, we work together with you in the design of the necessary animal toxicity studies of either your GLP or GMP produced compound This is critical step towards a phase 0 study in healthy human volunteers.